Isaac E. Kaba
About Isaac E. Kaba
Isaac E. Kaba is a Remote Research Investigator with a strong background in pharmaceutical sciences and medicinal chemistry. He has experience in cancer therapeutics research and has held various research positions at institutions such as The University of Toledo and Novartis Institutes for BioMedical Research.
Current Role at Yale University
Isaac E. Kaba is currently employed as a Remote Research Investigator at Yale University. He has held this position since 2023. In this role, he focuses on research initiatives that align with his expertise in medicinal chemistry and molecular pharmacology.
Education and Expertise
Isaac E. Kaba studied at the University of Kinshasa, where he earned an Associate of Science in Pharmaceutical Sciences from 2016 to 2019. He furthered his education at The University of Toledo, obtaining a Bachelor of Science with Honors in Pharmaceutical Sciences, along with a minor in Chemistry, from 2021 to 2023. His academic background provides a strong foundation for his research in small-molecule design and synthesis, particularly in cancer therapeutics.
Research Experience
Kaba has extensive research experience in various laboratories. He served as a Lead Investigator in the Cancer and Systems Therapeutics (CAST) Lab at The University of Toledo from 2022 to 2023. Additionally, he worked as a Research Assistant in the von Grafenstein Lab during the same period. His research contributions include a focus on the synthesis and structure-activity relationships of novel dual mechanism EZH2/AR inhibitors for prostate cancer.
Previous Positions in Pharmaceutical Research
Before his current roles, Kaba worked as a Summer Intern at Novartis Institutes for BioMedical Research (NIBR) in 2023. He also held the position of Lead Investigator at CESNOV in Kinshasa, Congo, from 2019 to 2020. His experience spans various research environments, contributing to his knowledge and skills in drug design and development.
Research Contributions and Goals
Isaac E. Kaba aims to contribute to the discovery and development of novel therapeutics to improve patient care. His research efforts are directed towards advancing cancer therapeutics through his expertise in medicinal chemistry and molecular pharmacology.